Engineering tiny 3D metallic parts
Peer-Reviewed Publication
Updates every hour. Last Updated: 2-Apr-2026 19:15 ET (2-Apr-2026 23:15 GMT/UTC)
Chimeric antigen receptor-invariant natural killer T cells, or CAR-iNKT cells, have shown promise in early studies, particularly against solid tumors that traditional CAR-T therapy struggles to treat. However, these cells often lose potency after delivery to a patient’s body. The UCLA team developed a system that functions like a charging station for these immune cells. Once implanted near a tumor, it attracts CAR-iNKT cells that have been engineered to recognize cancer. In the preclinical study, the platform demonstrated promising biocompatibility. The team is continuing to refine the system and explore how it could support additional cancer immunotherapies.